Biotech looks like chaos. No revenue, one drug, and a coin-flip catalyst that can make or break the company overnight. Most investors treat it like luck.

We don’t.



We quantify the noise: trial design, sample size, survival data, cash runway, dilution risk. From there we calibrate probabilities, backtest against history, and size positions accordingly.



Biotech isn’t a lottery. It’s a system. And systems can be traded.